Regenxbio
RGNX • NASDAQ
Regenxbio is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Curran Simpson, with a market cap of $400.5M.
CEOCurran Simpson
Next Earnings
Upcoming earnings announcement for Regenxbio
Date
Monday, May 11, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.39
Revenue Estimate
$24.7M
Earnings History
Past 12 earnings reports for Regenxbio
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$1.30Est: -$0.91 | -42.9% | $30.3MEst: $39.9M | -23.9% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$1.20Est: -$1.33 | +9.8% | $29.7MEst: $24.3M | +22.6% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$1.38Est: -$1.08 | -27.8% | $21.4MEst: $35.4M | -39.6% | 10-Q |
| May 12, 2025 | Q1 2025 | $0.12Est: $0.49 | -75.5% | $89.0MEst: $105.4M | -15.5% | 10-Q |
| Mar 13, 2025 | Q4 2024 | -$1.01Est: -$1.08 | +6.5% | $21.2MEst: $23.7M | -10.5% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$1.17Est: -$1.12 | -4.5% | $24.2MEst: $23.6M | +2.6% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$1.05Est: -$1.29 | +18.6% | $22.3MEst: $23.0M | -2.9% | 10-Q |
| May 8, 2024 | Q1 2024 | -$1.38Est: -$1.26 | -9.5% | $15.6MEst: $23.5M | -33.6% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$1.43Est: -$1.27 | -12.6% | $22.2MEst: $34.0M | -34.7% | 10-K |
| Nov 8, 2023 | Q3 2023 | -$1.41Est: -$1.49 | +5.4% | $28.9MEst: $27.2M | +6.3% | — |
| Aug 2, 2023 | Q2 2023 | -$1.66Est: -$1.26 | -31.7% | $20.0MEst: $39.8M | -49.8% | 10-Q |
| May 3, 2023 | Q1 2023 | -$1.53Est: -$1.54 | +0.6% | $19.1MEst: $30.6M | -37.5% | — |